Cytek Biosciences, Inc.
CTKB
$4.30
-$0.06-1.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,005.30% | -26.18% | 63.53% | 2.23% | 50.44% |
| Total Depreciation and Amortization | 14.16% | 14.73% | 15.09% | 10.37% | 13.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 314.31% | -74.27% | -54.19% | -37.41% | -29.46% |
| Change in Net Operating Assets | -162.15% | -172.74% | -99.65% | 172.00% | 173.39% |
| Cash from Operations | -118.46% | -105.83% | -1.51% | 233.81% | 380.57% |
| Capital Expenditure | -15.86% | 3.73% | 2.67% | 19.17% | 24.16% |
| Sale of Property, Plant, and Equipment | -12.50% | 155.67% | 252.63% | -- | -- |
| Cash Acquisitions | -- | -99.58% | -98.73% | -98.73% | 98.96% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 117.60% | -442.69% | -211.77% | -186.03% | -79.68% |
| Cash from Investing | 112.19% | -640.41% | -225.92% | -197.89% | 11.63% |
| Total Debt Issued | 33.51% | 397.92% | 249.75% | 149.43% | -- |
| Total Debt Repaid | -751.89% | -248.39% | -248.74% | -246.95% | 1.42% |
| Issuance of Common Stock | -45.79% | -42.90% | -47.54% | -37.89% | -18.18% |
| Repurchase of Common Stock | 28.97% | 54.64% | 25.41% | 26.62% | 50.27% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 15.11% | 65.50% | 29.09% | 27.91% | 62.16% |
| Foreign Exchange rate Adjustments | -97.59% | -90.19% | -134.16% | 20.07% | 413.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.54% | -5,105.35% | -320.92% | -300.95% | 47.76% |